Cardinal Health price target raised to $130 from $129 at Baird

Baird raised the firm’s price target on Cardinal Health to $130 from $129 and keeps an Outperform rating on the shares. The firm said with prior segment reclassification done, OptumRx contracts decision known, FY24 guidance recently raised, and preliminary FY25 baseline expectations set, they expect a relatively calmer distributor quarter after heightened company-specific and sector noise year-to-date.